71 related articles for article (PubMed ID: 38474118)
21. MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside.
Hardy-Werbin M; Del Rey-Vergara R; Galindo-Campos MA; Moliner L; Arriola E
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31547040
[TBL] [Abstract][Full Text] [Related]
22. Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases.
Whang YM; Jung SP; Kim MK; Chang IH; Park SI
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658428
[TBL] [Abstract][Full Text] [Related]
23. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities.
Zhang Y; Xia M; Jin K; Wang S; Wei H; Fan C; Wu Y; Li X; Li X; Li G; Zeng Z; Xiong W
Mol Cancer; 2018 Feb; 17(1):45. PubMed ID: 29455668
[TBL] [Abstract][Full Text] [Related]
24. Role of c-Met in the progression of human oral squamous cell carcinoma and its potential as a therapeutic target.
Sun Z; Liu Q; Ye D; Ye K; Yang Z; Li D
Oncol Rep; 2018 Jan; 39(1):209-216. PubMed ID: 29115556
[TBL] [Abstract][Full Text] [Related]
25. A Combination of Two Receptor Tyrosine Kinase Inhibitors, Canertinib and PHA665752 Compromises Ovarian Cancer Cell Growth in 3D Cell Models.
Hassan W; Chitcholtan K; Sykes P; Garrill A
Oncol Ther; 2016; 4(2):257-274. PubMed ID: 28261654
[TBL] [Abstract][Full Text] [Related]
26. Understanding c-MET signalling in squamous cell carcinoma of the head & neck.
Szturz P; Raymond E; Abitbol C; Albert S; de Gramont A; Faivre S
Crit Rev Oncol Hematol; 2017 Mar; 111():39-51. PubMed ID: 28259294
[TBL] [Abstract][Full Text] [Related]
27. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
International Cancer Genome Consortium PedBrain Tumor Project
Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748
[TBL] [Abstract][Full Text] [Related]
28. Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling.
Kim B; Jung N; Lee S; Sohng JK; Jung HJ
Phytother Res; 2016 Nov; 30(11):1833-1840. PubMed ID: 27468969
[TBL] [Abstract][Full Text] [Related]
29. MET Inhibition in Clear Cell Renal Cell Carcinoma.
Xie Z; Lee YH; Boeke M; Jilaveanu LB; Liu Z; Bottaro DP; Kluger HM; Shuch B
J Cancer; 2016; 7(10):1205-14. PubMed ID: 27390595
[TBL] [Abstract][Full Text] [Related]
30. The expanding role of mTOR in cancer cell growth and proliferation.
Cargnello M; Tcherkezian J; Roux PP
Mutagenesis; 2015 Mar; 30(2):169-76. PubMed ID: 25688110
[TBL] [Abstract][Full Text] [Related]
31. mTOR: a pharmacologic target for autophagy regulation.
Kim YC; Guan KL
J Clin Invest; 2015 Jan; 125(1):25-32. PubMed ID: 25654547
[TBL] [Abstract][Full Text] [Related]
32. EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Nishimura Y; Takiguchi S; Ito S; Itoh K
Int J Oncol; 2015 Apr; 46(4):1721-9. PubMed ID: 25653196
[TBL] [Abstract][Full Text] [Related]
33. MET: a critical player in tumorigenesis and therapeutic target.
Graveel CR; Tolbert D; Vande Woude GF
Cold Spring Harb Perspect Biol; 2013 Jul; 5(7):. PubMed ID: 23818496
[TBL] [Abstract][Full Text] [Related]
34. Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma.
Gao W; Bing X; Li M; Yang Z; Li Y; Chen H
Med Oncol; 2013 Jun; 30(2):546. PubMed ID: 23536000
[TBL] [Abstract][Full Text] [Related]
35. Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cells.
Humbert M; Medová M; Aebersold DM; Blaukat A; Bladt F; Fey MF; Zimmer Y; Tschan MP
Biochem Biophys Res Commun; 2013 Feb; 431(2):264-9. PubMed ID: 23313490
[TBL] [Abstract][Full Text] [Related]
36. MUC1 drives c-Met-dependent migration and scattering.
Horm TM; Bitler BG; Broka DM; Louderbough JM; Schroeder JA
Mol Cancer Res; 2012 Dec; 10(12):1544-54. PubMed ID: 23193156
[TBL] [Abstract][Full Text] [Related]
37. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Zhang S; Yu D
Trends Pharmacol Sci; 2012 Mar; 33(3):122-8. PubMed ID: 22153719
[TBL] [Abstract][Full Text] [Related]
38. An overview of the c-MET signaling pathway.
Organ SL; Tsao MS
Ther Adv Med Oncol; 2011 Nov; 3(1 Suppl):S7-S19. PubMed ID: 22128289
[TBL] [Abstract][Full Text] [Related]
39. c-MET: an exciting new target for anticancer therapy.
de Bono JS; Yap TA
Ther Adv Med Oncol; 2011 Nov; 3(1 Suppl):S3-5. PubMed ID: 22128286
[No Abstract] [Full Text] [Related]
40. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.
Liu X; Wang Q; Yang G; Marando C; Koblish HK; Hall LM; Fridman JS; Behshad E; Wynn R; Li Y; Boer J; Diamond S; He C; Xu M; Zhuo J; Yao W; Newton RC; Scherle PA
Clin Cancer Res; 2011 Nov; 17(22):7127-38. PubMed ID: 21918175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
